Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

15.8%

3 terminated out of 19 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

26%

5 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed with results

Key Signals

4 with results67% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (1)
P 1 (2)
P 2 (5)
P 3 (4)
P 4 (1)

Trial Status

Completed6
Recruiting5
Terminated3
Unknown2
Not Yet Recruiting1
Active Not Recruiting1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT01915225Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

NCT05152147Phase 3Active Not RecruitingPrimary

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT04949737Recruiting

Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies

NCT07312370Phase 4Not Yet Recruiting

Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing

NCT03615326Phase 3CompletedPrimary

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT06848400Not ApplicableRecruiting

Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

NCT07001592Phase 1RecruitingPrimary

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

NCT04180761Phase 2WithdrawnPrimary

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

NCT04535414Phase 2Completed

Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers

NCT05551416RecruitingPrimary

The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer

NCT03019588Phase 3TerminatedPrimary

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

NCT03817866CompletedPrimary

Chromogranin A as Blood Marker in Cancer Patients

NCT05111444Phase 2UnknownPrimary

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT03648879Phase 2Completed

Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome

NCT02900248Terminated

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

NCT02488746TerminatedPrimary

Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)

NCT01614522Phase 2Completed

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

NCT02005809Phase 3UnknownPrimary

Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm

NCT01166490Phase 1CompletedPrimary

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

Showing all 19 trials

Research Network

Activity Timeline